Back to top
more

Biohaven Ltd. (BHVN)

(Delayed Data from NYSE)

$38.97 USD

38.97
948,302

+0.43 (1.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.98 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?

Biohaven Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?

Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization

The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.

Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.

Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should iShares Morningstar SmallCap Growth ETF (ISCG) Be on Your Investing Radar?

Style Box ETF report for ISCG

Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?

Style Box ETF report for ISCB

Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Doximity (DOCS) to Report Q1 Earnings: What's in the Offing?

Doximity's (DOCS) fiscal first-quarter results are likely to reflect continued strength in its fax, e-signature and telehealth products.

Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?

Style Box ETF report for IWM

AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine

AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.

Biohaven (BHVN) Begins Phase III Study on SMA Candidate

Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.

Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA

The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.

The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical

Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog

Ekta Bagri headshot

Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News

Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.

Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider

Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?